| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = -$104,283 ) |
| | 2021 | 2019 | UNIVERSITATSKLINIKUM ERLANGEN | MAXIMILIANSPLATZ 2 | ERLANGEN | BAYERN | | | DEU | R21AI136674 | Global panel of non-human primate challenge viruses for standardized assessment of in vivo efficacy of HIV-1 Env antibodies | 000 | 3 | NIH | 8/11/2021 | -$104,283 |
|
| Issue Date FY: 2019 ( Subtotal = $178,041 ) |
| | 2019 | 2019 | UNIVERSITATSKLINIKUM ERLANGEN | MAXIMILIANSPLATZ 2 | ERLANGEN | BAYERN | 91054 | | DEU | R21AI136674 | Global panel of non-human primate challenge viruses for standardized assessment of in vivo efficacy of HIV-1 Env antibodies | 000 | 3 | NIH | 1/21/2019 | $178,041 |
|
| Issue Date FY: 2018 ( Subtotal = $99,023 ) |
| | 2018 | 2018 | UNIVERSITATSKLINIKUM ERLANGEN | MAXIMILIANSPLATZ 2 | ERLANGEN | BAYERN | 91054 | | DEU | R21AI136674 | Global panel of non-human primate challenge viruses for standardized assessment of in vivo efficacy of HIV-1 Env antibodies | 002 | 2 | NIH | 7/6/2018 | $99,023 |
|
|
